Company Snapshot: Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the outpatient diabetes market and in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
- Dec 21 2016 Echo Therapeutics Announces Dismissal of Federal Court Action
- Dec 12 2016 Echo Therapeutics Announces Federal Court's Denial Of Preliminary Injunction And Lifting Of Temporary Restraining Order
- Aug 12 2016 Echo Therapeutics, Inc. Announces Second Quarter 2016 Financial Results
- Jul 8 2016 Echo Therapeutics Common Stock to Transition from NASDAQ to OTCQB